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We are reporting a case of an 18-month old male who
presented with bilateral cryptorchidism. The patient
underwent an explorative laparoscopy in which two gonads
were identified in close proximity to the uterus and
fallopian tubes. Biopsy of the gonads confirmed testicular
tissue. Genetic analysis demonstrated a 46, XY male. Male
external genitalia were appropriate for age with no
evidence of female structures. Persistent Mullerian duct
syndrome is extremely rare, with approximately 260 cases
reported in the literature. Best practice for the extent of
surgical management is still evolving as we gather data on
long-term outcomes. Ann Pediatr Surg 14:24–26 c 2018
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Introduction
Persistent Mullerian duct syndrome (PMDS) is a rare
case of male pseudohermaphroditism. Patients have a
46, XY karyotype and are phenotypically male. However,
internally they have remnant Mullerian structures,
including uterus, fallopian tubes, and proximal vagina,
which typically outflow into the prostatic urethra [1].
Approximately 260 cases have been reported [2]. It is
commonly discovered in adulthood as an incidental
finding during an inguinal hernia repair or orchiopexy
for unilateral or bilateral cryptorchidism. Patients have
normal male phenotype and undergo normal puberty with
normal virilization; however, infertility is common [3].
Case presentation
An 18-month old male was referred to the pediatric
surgery clinic for bilateral cryptorchidism. The patient
had no significant medical or surgical history and no
family history of cryptorchidism. On physical examina-
tion, the patient appeared healthy, well developed, well
nourished, and of appropriate size and weight for age.
Physical examination was unremarkable, except for an
empty an scrotum bilaterally with no testes palpated in
the scrotum or groin. No hernia was identified on either
side. The patient was taken to the operating room for
exploratory laparoscopy with possible orchiopexy. Two
intra-abdominal testes were identified. Upon difficulty
inserting the testes into the inguinal ring, closer
investigation revealed that the testes were in commu-
nication through a midline structure. Because of poor
visualization, testicle and the midline structure were
brought to surface via a 3-cm lower quadrant excision.
The testicle was embedded in a ligament and was
attached to what appeared to be a uterus and fallopian
tube (Figs 1 and 2). Testicular vessels were identified;
however, vas deferens was not distinctly recognized. A
biopsy of the testicle was taken for confirmation.
Contents were placed back inside the pelvis and the
operation was concluded. Pathologic evaluation of the
gonadal tissue was consistent with testicular tissue with
no evidence of ovarian tissue. The patient underwent a
genotypic analysis, which revealed a normal 46, XY
karyotype. The patient was diagnosed with PMDS.
Discussion
During embryologic development, the fetus contains both
mesonephric (Wolffian) and paramesonephric (Mullerian)
ducts. In a 46, XY male, the SRY gene on the Y
chromosome produces testis-determining factor, which
leads to the development of the testes. The testes are
made of two compartments: seminiferous tubules, which
enclose Sertoli cells, and interstitial tissue, which house
Leydig cells [4]. Sertoli cells secrete anti-Mullerian
hormone (AMH), also known as Mullerian inhibiting
substance or factor, which suppresses the development
of paramesonephric ducts, thereby inhibiting the forma-
tion of female internal structures, notably the uterus,
fallopian tubes, and proximal vagina. Leydig cells secrete
androgens that stimulate the development of mesonephric
ducts, leading to the formation of male internal structures,
including the seminal vesicles, epididymis, ejaculatory
duct, and vas deferens. Androgens are converted to
dihydrotestosterone to allow the urogenital sinus and
genital tubercle to form the prostate and male external
genitalia, respectively [5].
Female phenotype is the default phenotype, where even
a 46, XY male will develop internal female structures if he
has a defective SRY gene, Sertoli cells that fail to produce
functional AMH, or have defective type II AMH
receptors (AMH-IIR) [6]. In all, 85% of PMDS cases
are due to a nonfunctional mutation in AMH or AMH-IIR
gene that has autosomal recessive transmission. The
remaining 15% of cases are idiopathic [7].
PMDS is typically discovered incidentally during an
inguinal hernia repair or orchiopexy. Clinically, patients
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have normal growth and development without any external
deficiencies. Upon identification, PMDS is divided into
classes: class A (60–70%) – bilateral undescended testicles
embedded in the broad ligament located in the area
analogous to ovaries in a female; class B (20–30%) –
unilateral undescended testicle with ipsilateral inguinal
hernia that may contain the testis, uterus, and fallopian
tubes (i.e. hernia uteri inguinale); and class C (10%) –
involves transverse testicular ectopia with both testes in
the same hernia sac along with Mullerian structures [8].
Management of the patient with PMDS is still under
discussion. Depending on the age of diagnosis, orchiopexy
or orchiectomy should be performed to help preserve
fertility or eliminate the possibility of testicular malignan-
cies, respectively. With regard to Mullerian structures,
initially nonoperative management was favored because of
difficulty in identifying the vas deferens, as many times it is
found intimately adherent to lateral walls of the uterus or
the fallopian tubes, and risk of damage to the vas deferens
and testicular vesicles may lead to infertility and significant
morbidity. In addition, it was believed that retention of
Mullerian remnants was low risk [1]. However, 11 cases of
advanced malignancies stemming from these remnants,
even in the pediatric population, have been identified,
many of which within the past two decades [2,8].
Furthermore, patients with PMDS are at a greater risk for
Mullerian malignancy than testicular malignancy, resulting
in increasing support for surgical intervention [9,10].
The majority of interventions have been staged, with
stage 1 involving gonadal biopsy and hernia repair and
stage 2 addressing the testes and Mullerian remnants. Of
note, Manjunath et al. [8] argue that if the epididymis and
vas deferens are present, this would unequivocally reveal
that the gonads are testes, and a staged procedure is not
needed as orchiopexy can be performed during initial
exploration. This would eliminate the need for a biopsy
and prevents insult to the blood–testes barrier and the
possibility of forming antisperm antibodies, which would
further decrease fertility [11]. Guerrier et al. [12] ad-
vocate bilateral proximal salpingectomies, leaving fim-
briae with the epididymis, hysterectomy, and bilateral
orchiopexy, if the testes are normal. If the testes are
atrophic, orchiectomy should be performed. Risk of
testicular malignancy in patients with PMDS is 5–18%,
similar to that of patients with cryptorchidism [2]. Many
patients present with neglected cryptorchidism (mean
age 8.2 years in one study) and have short spermatic
vessels, necessitating a staged Fowler–Stephens orchio-
pexy (FSO) [2]. However, dissection of Mullerian
remnants would significantly risk damage to the defer-
ential vessels, the remaining blood supply to the testes.
Because of greater likelihood of testicular atrophy if FSO
and Mullerian remnant excision are being done together,
Shalaby et al. [2] advocate for leaving the Mullerian
remnants in place whenever FSO is necessary and opt for
long-term follow-up. Manjunath et al. [8] advocate for
removal of remnants that can be safely removed, without
risking damage to the vas deferens or testicular blood
supply, and stripping/destroying the mucosa of the
retained Mullerian remnants to reduce the risk of
malignancy, which originate from the mucosa. Subse-
quently demonstrating that in patients where FSO is
necessary, a midline splitting of the Mullerian remnants
with obliteration of mucosa would allow for complete
mobilization of both testes without risking damage to the
vas deferens or testicular blood supply [8].
Fig. 2
Testicle embedded in a ligament and attached to what appears to be a
uterus and fallopian tube. Right clamp indicating the fallopian tube.
Fig. 1
Testicle embedded in a ligament and attached to what appears to be a
uterus and fallopian tube. Clamp indicates testicular vessels.
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Conclusion
The treatment plan for our patient is to perform
laparoscopic total abdominal hysterectomy with bilateral
proximal salpingectomy and bilateral orchiopexy.
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